Spine Biologics Market Overview
Spine Biologics Market size is estimated to reach $3.4 billion by 2027, growing at a CAGR of 4.3% during the forecast period 2022-2027. Spine biologics are materials that change the encircling surroundings by way of active cellular procedures. They advance development and distinction and support in the restoration and curing of an injury. They also decrease the frequency of primary or added surgical processes and diminish the disruption of soft tissue. Degenerative disc diseases are conditions where one or more discs in the spine decay owing to age, which leads to back or neck pain. Degenerative disc diseases are when the spinal disks deteriorate down. Biomolecular therapies (for example genes and proteins), cell-based therapies, (for example stem cells and chondrocytes), and total disc replacement (allogeneic or tissue-engineered) are the expansive classifications of research in biologics for degenerative disc diseases. Pediatric spinal fusions have been linked with nonunion rates of nearly 25%, positioning patients at hazard for neurological complexities while concurrently acquiring considerable costs for revision surgery. In an endeavor to reduce nonunion rates, different bone grafts and biologics have been established to raise osseous formation and arthrosis. The present gold standard in bone grafting is autologous bone taken from the iliac crest or ribs, however, this process is related to significant morbidity and postoperative pain owing to an added graft harvesting process. Additional bone graft substitutes and biologics involve allografts, demineralized bone matrix, bone morphogenetic protein, and bioactive glass. Platelet-rich plasma (PRP) is an autologous blood concentrate that includes a natural concentration of autologous development factors and cytokines. PRP has been extensively utilized in the clinical setting for tissue regeneration and repair. Currently, specifically in the field of sports medication and orthopedics, PRP has displayed the regenerative capability to restore damaged tissues, inclusive of tendons, ligaments, and cartilage, all of which have a reduced intrinsic healing possibility. PRP has currently been utilized in the treatment of Achilles and patella tendinopathies.
The expanding population of the elderly is set to drive the Spine Biologics Market. The increasing predominance of spine deformities including degenerative disc diseases and technological progress in bone-grafting processes are set to propel the growth of the Spine Biologics Market during the forecast period 2022-2027. This represents the Spine Biologics Industry Outlook.
The report: “Spine Biologics Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Spine Biologics Market.
- Geographically, North America Spine Biologics Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the existence of the population of senior citizens enduring degenerative disc diseases and rising acceptance of minimally invasive process in the North American region.
- Spine Biologics Market growth is being driven by the increasing predominance of degenerative disc diseases and a consequent rise in treatment rates. However, unsupportive reimbursement scenario, the greater cost of the bone grafts, and some ethical issues associated with bone grafting procedures are some of the major factors hampering the growth of the Spine Biologics Market.
- Spine Biologics Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Spine Biologics Market report.
For More Details on This Report - Request for Sample
Spine Biologics Market Segment Analysis – By Product:
The Spine Biologics Market based on product can be further segmented into Bone Graft Substitutes, Spinal Allografts, Cell-Based Matrix, and Others. The Spinal Allografts (ECG) Segment held the largest market share in 2021. This growth is owing to the surging application of spinal allografts attributed to its many advantages. Cases of degenerative disc diseases are observed. The soaring advantages of allografts over autografts attributed to characteristics like immediate structural support and osteoconductivity and the non-requirement of another surgery to harvest the bone leading to decreased surgery duration and wound healing are further propelling the growth of the Spinal Allografts segment.
Furthermore, the Bone Graft Substitutes segment is estimated to grow with the fastest CAGR of 5.7% during the forecast period 2022-2027 owing to the soaring acceptance by surgeons and an increasing count of spinal fusion procedures.
Spine Biologics Market Segment Analysis – By End User:
The Spine Biologics Market based on end user can be further segmented into Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Spinal Surgery Centers, and Others. The Hospitals segment held the largest market share in 2021. This growth is owing to the increasing count of spinal fusion surgeries performed in hospitals. Cases of degenerative disc diseases may also be examined in hospitals. The well-established medical infrastructure and the easy availability of qualified and skilled physicians are further propelling the growth of this segment.
Furthermore, the Ambulatory Surgical Centers segment is estimated to grow with the fastest CAGR of 6.2% during the forecast period 2022-2027 owing to the increasing demand for minimally invasive surgeries, technological developments in surgical devices and equipment, the surgeon’s control over the selection of equipment and the increasing count of cases of spinal ailments like degenerative disc diseases.
Spine Biologics Market Segment Analysis – By Geography:
The Spine Biologics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and Rest of the World. North America (Spine Biologics Market) held the largest share with 34% of the overall market in 2021. The growth of this region is owing to the expanding population of the elderly and the surging acceptance of minimally invasive procedures in the North American region. The increasing predominance of spine ailments like degenerative disc diseases with the largest market for Spine Biologics being the U.S. in the North American region is further propelling the growth of the Spine Biologics Market in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the existence of an enormous patient pool and the proliferating awareness among surgeons and patients regarding the advantages of biologics in the Asia-Pacific region. The increasing pervasiveness of spine ailments like degenerative disc diseases and spinal injuries specifically owing to road mishaps are further fuelling the progress of the Spine Biologics Market in the Asia-Pacific region.
Spine Biologics Market Drivers
Surging Innovative Biological Treatment Techniques For Degenerative Disc Disease Are Projected To Drive The Growth Of Spine Biologics Market:
As per facts regarding degenerative disc diseases on www.healthgrades.com, “By age 60, more than 90% of people show evidence of disc disintegration.” Low back pain is the chief cause of work absences and years lived with disability, and it is frequently related to degenerative disc disease. In current years, biological treatment approaches like the application of growth factors, cell injections, annulus fibrosus (AF) repair, nucleus pulposus replacement, and tissue-engineered discs have been explored as means for avoiding or reversing degenerative disc disease. Both animal and clinical investigations have demonstrated promising outcomes for cell-based therapy on the grounds of its regenerative potential. Clinical data also signify that stem cell injection is secure when suitably carried out, although its long-term security and efficacy are yet to be investigated. AF repair techniques inclusive of devices utilized in clinical trials have demonstrated success in reducing reherniation rates and enhancing complete clinical outcomes. Additionally, current investigations that integrated AF repair and nucleus pulposus replacement have demonstrated enhanced biomechanical stability in IVDs after the integrated treatment. The surging innovative biological treatment techniques for degenerative disc disease are therefore fuelling the growth of the Spine Biologics Market during the forecast period 2022-2027.
Proliferating Applications Of Biologics In Spinal Fusions Are Expected To Boost The Demand For Spine Biologics:
An estimated 200,000 spinal fusions are carried out in the U.S. yearly for a big series of pathologic conditions. The goal of spinal fusion is to repair or improve spinal stability by developing a bony union between two or more vertebrae. Pseudoarthrosis, failure of spinal fusion, can result in persistent symptoms and disability, frequently needing revision surgery. The biology of spinal fusion is a complicated procedure including steps similar to bone healing subsequent to fracture. Numerous methods are applied to improve the success of spinal fusion, inclusive stabilization with metallic or polymeric implants, grafting with bone products, and augmentation with an assortment of biological agents. Bone grafts used can be autologous or allogenic and are frequently manipulated to eliminate mineral content and/or keep up a cell population to improve fusion. Synthetic biologics products are typically constituted of ceramic or bioactive glass. Recombinant growth factors, most typically bone morphogenic protein-2, are potent stimulators of bone formation, however, may have an important risk profile. In current years, one of the inspiring developments in the spine field has been the rise of the application of biologic materials in spine surgery. The proliferating applications of biologics in spinal fusions are therefore driving the growth of the Spine Biologics Market during the forecast period 2022-2027.
Spine Biologics Market Challenges
Limitations Of Bone Grafting Are Hampering The Growth Of The Spine Biologics Market:
There are certain limitations to allografts. Owing to allografts being derived from human origin, they are both osteoconductive and weakly osteoinductive. However, owing to the sterilization procedure, allografts are deficient in viable cells and have no osteogenic characteristics. Additional limitations of allografts involve the restricted hazard of HBV or HCV infection from the donor and the possibility of adverse altering of the bone matrix composition at the time of the procedure of sterilization with chemicals and radiation. With regard to Iliac Crest Bone Grafts (ICBGs), the iliac crest is the most typical site for autograph harvest. However, there are numerous recorded complexities of harvesting from the iliac crest inclusive of the development of infections, seromas, hematomas, and fractures to the iliac spine with recorded complication rates of 1.40%, 0.64%, 1.49%, and 0.16%, respectively, with some needing further operative management. These issues are thus hampering the growth of the Spine Biologics Market.
Spine Biologics Industry Outlook:
Innovative product launches, collaborations, mergers and acquisitions and R&D activities are key strategies adopted by players in the Spine Biologics Market. Key companies of this market are:
- Stryker Corporation
- Orthofix Holdings Inc.,
- NuVasive, Inc.
- K2M Inc.
- DePuy Synthes
- Zimmer Biomet
- Arthrex, Inc.
- Exactech, Inc
- Medtronic plc
- Lattice Biologics Ltd.
- In March 2022, Stryker's Joint Replacement Division presently declared the launch of the Insignia® Hip Stem, engineered to optimize patient fit and surgeon ease of implantation in muscle-sparing approaches for total hip and hemiarthroplasty procedures, at the American Academy of Orthopaedic Surgeons (AAOS) 2022 Annual Meeting in Chicago. Insignia is compatible with Mako SmartRobotics™ utilizing Total Hip 4.1 software, which permits surgeons to utilize data from a 3D CT-based plan to capture every patient's rare anatomy. Using Stryker's proprietary Orthopaedics Modeling and Analytics (SOMA) database, Stryker assessed data from over 1,300 patient CT scans and worked to plan a device that efficiently recreates patient biomechanics for total hip replacement processes.
- In May 2021, Stryker declared presently the gain of OrthoSensor, Inc., a privately held firm founded in 2007 and headquartered in Dania Beach, FL. OrthoSensor, Inc., is a leader in the digital evolution of musculoskeletal care and sensor technology for complete joint replacement. OrthoSensor quantifies orthopedics by way of intelligent devices and data services that permit surgeons and hospitals to distribute evidence-based treatments for all healthcare stakeholders.
- In November 2020, Stryker declared presently that it has finished the formerly declared gain of Wright Medical Group N.V., a global medical device firm directed on extremities and biologics. Wright Medical brings a great complementary product portfolio and consumer base to Stryker’s trauma and extremities business. The firm is an acknowledged leader in the upper extremities (shoulder, elbow, wrist, and hand), lower extremities (foot and ankle), and biologics market segments, which are among the fastest-growing segments in orthopedics.
Report Code: HCR 0098
Report Code: HCR 40151
Report Code: HCR 22885